2. Mergers and acquisitions are picking up: So far this year, buyouts have boosted several biotech stocks. Some standouts: Regulus Therapeutics went up 120%; 89bio went up 85%; Chimerix gained 69% and ...

Biotech company Amgen (NASDAQ:AMGN) beat Wall Street’s revenue expectations in Q3 CY2025, with sales up 12.4% year on year to $9.56 billion. The company’s full-year revenue guidance of $36.2 billion ...

The group says its vaccine business will recover in the medium term when falling immunisation rates cause a severe public ...

Once this policy is enacted, it will be illegal for Americans to retain any mental impression longer than that little haptic ...

It is a smart strategy to diversify your portfolio by investing in high-quality companies built on proven technologies.

Sarepta Therapeutics, Inc. faces revenue decline, trial setbacks, and FDA decisions. Click for SRPT risks, outlook, and if ...

Aurinia alleges that Tidmarsh’s statements were not only inaccurate but also motivated by a personal vendetta against Kevin ...

Global stocks mostly fell Tuesday as investors weighed the recent tech rally on Wall Street against growing fears of an AI ...

The biotechnology company posted revenue of $159.9 million in the period, also missing Street forecasts. Eight analysts surveyed by Zacks expected $167.6 million. Ultragenyx expects full-year revenue ...

Two scientists argue that the growing commercial efforts to counter climate change by reflecting away sunlight will thwart ...

On a per-share basis, the Thousand Oaks, California-based company said it had net income of $5.93. Earnings, adjusted for non-recurring gains, were $5.64 per share. The results surpassed Wall Street ...

Businesses have warned it is increasingly difficult to operate following tax rises in the last Budget, alongside higher ...